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Background. Studies have suggested that albumin has a value in cirrhotic patients undergoing paracentesis but its value in infection
and sepsis is less clear. We planned to perform a meta-analysis of the risk of adverse outcomes in cirrhotic patients with and
without albumin use.Methods.We searched MEDLINE and EMBASE in January 2013 for randomized studies of cirrhotic patients
that reported the risk of adverse events and mortality with albumin and no albumin exposure. We performed random effects
meta-analysis and assessed heterogeneity using the I2 statistic. Results. Our review included 16 studies covering 1,518 patients. The
use of albumin in paracentesis was associated with significantly reduced risk of paracentesis-induced circulatory dysfunction (OR
0.26 95%, CI 0.08–0.93) and there was a nonsignificant difference in death, encephalopathy, hyponatraemia, readmission, and renal
impairment. Compared to the other volume expanders, albumin use showed no difference in clinical outcomes. In cirrhotic patients
with any infection, there was a significant reduction inmortality (OR 0.46 95%, CI 0.25–0.86) and renal impairment (OR 0.34 95%,
CI 0.15–0.75) when albumin was used.Conclusion.Theuse of albumin in cirrhotic patients is valuable in patients with any infection
and it reduces the risk of circulatory dysfunction among patients undergoing paracentesis.
1. Introduction
Intravenous administration of human albumin solution is
frequently used in patients with decompensated liver cir-
rhosis during the drainage of ascites. In the absence of
intravenous albumin, postparacentesis circulatory dysfunc-
tion occurs in approximately 70% of patients [1, 2] and is
associated with increased mortality because of hepatorenal
syndrome and dilutional hyponatraemia [3, 4]. In addition,
albumin administration is recommended in patients with
spontaneous bacterial peritonitis (SBP) [5, 6].
Albumin is a plasma expander that increases car-
diac preload and peripheral vascular resistance, attenuates
endothelial dysfunction, reduces renal failure, and improves
survival [7, 8]. As a result, albumin is widely accepted as
a therapy in large volume paracentesis and spontaneous
bacterial peritonitis, but the evidence supporting this therapy
in other settings is less clear.
Bacterial infections are common in patients with
advanced cirrhosis and are a major cause of hospital
admissions and mortality [9–12]. Approximately 30–40% of
cirrhotic patients with severe infection develop renal failure
and this is a poor prognostic factor [13–16]. The infection
that most often causes renal failure is spontaneous bacterial
peritonitis, followed by urinary tract infection and cellulitis.
Few data exist regarding the effect of albumin adminis-
tration in patients with non-SBP infections. The question of
whether albumin infusion also improves outcome in patients
with bacterial infections other than SBP remains unanswered.
Studies to date failed to answer this question due to small
sample size [17] and further research should be performed to
answer this question.
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In this systematic review, we provide a comprehensive
and up-to-date overview of the existing evidence regarding
the use of albumin in cirrhotic patients. We were specifi-
cally interested in three questions. Is albumin beneficial in
cirrhotic patients undergoing large volume paracentesis? Is
albumin useful in cirrhotic patients with infections, with
particular focus on SBP and non-SBP infections? Is albumin
superior to other volume expanders in cirrhotic patients?
2. Methods
2.1. Eligibility Criteria. We selected randomized controlled
trials (RCTs) that evaluated the use of human serum albumin
in patients with cirrhosis. The specific inclusion criteria for
the studies were (1) parallel group randomized trial with
albumin in one of the treatment arms for any duration of
therapy; (2) placebo or alternative control arm; (3) clear
reporting of adverse events. The adverse events of interest
were death, encephalopathy, hyponatraemia, paracentesis-
induced circulatory dysfunction, readmission, renal impair-
ment, gastrointestinal bleeding, infection resolution, and
sepsis/severe infection. There was no restriction on cirrhotic
patients and those with tense ascites requiring paracentesis,
and those with infections including SBP were included.
2.2. Search Strategy. We searched MEDLINE and EMBASE
through OvidSP in January 2013 using the Haynes opti-
mized search strategy (Health Information Research Unit,
McMaster University) (see Supplementary Material 1 avail-
able online at http://dx.doi.org/10.1155/2013/295153) [18]. We
also checked the bibliographies of the included trials and
recent review articles for relevant studies.
2.3. Study Selection and Data Extraction. One reviewer
(Chun Shing Kwok) and one of two other reviewers (Ash
Mahtani or Duncan Kaye) independently scanned all titles
and abstracts for studies that met the inclusion criteria and
excluded any articles that clearly did not fulfil the selection
criteria. Full reports of potentially relevant trials and studies
were retrieved and independently checked by two reviewers
(Lukasz Krupa andWilliam Gelson). We then independently
collected information on study design, drug exposure, study
location, characteristics of participants, and relevant out-
comes onto a spreadsheet (Chun Shing Kwok, Ash Mahtani,
and Duncan Kaye). Where there was any uncertainty or
discrepancies, the articlewas discussed between the reviewers
(Lukasz Krupa, Simon M. Rushbrook, Martin G. Phillips,
and William Gelson) to determine if the studies should be
included. We also contacted authors if there were any areas
that required clarification.
2.4. Risk of Bias Assessment. We evaluated the quality of
studies in accordance with the recommendations of the
Cochrane Handbook and this assessment included sequence
generation, allocation concealment, blinding of participant,
personnel and outcome assessors, incomplete outcome data,
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from PubMed 
Articles selected after screening of title and 
Articles excluded after detailed screening to 
16 different articles selected for inclusion in 
the meta-analysis
Articles retrieved 
from Embase search 
search (N = 223)
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specific criteria (N = 39)
(N = 500)
Figure 1: Flow diagram of the process of article selection for meta-
analysis.
selective reporting, and baseline differences in participants
[32].
We aimed to generate funnel plots to assess the possibility
of publication bias, provided that there were >10 studies
available in themeta-analysis, with no evidence of substantial
statistical heterogeneity.
2.5. Data Analysis. We used RevMan 5.022 (Nordic
Cochrane Centre) to conduct random effects meta-analysis
using pooled odds ratios (OR). We chose to pool raw
outcome data to yield unadjusted risk ratios (which may
be particularly susceptible to confounding). In view of the
potential diversity of study participants and interventions,
we chose to perform sensitivity analysis based on groupings:
(1) cirrhotic patients receiving paracentesis,
(2) cirrhotic patients receiving albumin compared to
other volume expanders,
(3) cirrhotic patients with infections, SBP, and non-SBP
infections.
2.6. Statistical Heterogeneity. Statistical heterogeneity was
assessed using 𝐼2 statistic, with 𝐼2 values of 30–60% repre-
senting a moderate level of heterogeneity [33].
3. Results
The search results yielded 16 relevant RCTs with 1,518 patients
from Egypt, France, Korea, Argentina, Mexico, Spain, USA,
Italy, andChina. Four studies [2, 21, 23, 30] evaluated albumin
versus no albumin/saline, and eight studies [19, 20, 22, 24,
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Table 1: Study design, patient characteristics and selection criteria.
Study Design; year of study;country Number of participants
Mean
age
Male
% Selection criteria
Abdel-Khalek and
Arif 2010 [19]
Randomized trial; Apr 2008
to Feb 2009; Egypt.
135; 68 albumin; 67
hydroxyethyl starch. 47 79
Patients with cirrhosis and tense
ascites which were unresponsive to
low-sodium diet and diuretic therapy.
Altman et al. 1998
[20]
Randomized trial; unclear
dates; France.
65; 33 albumin; 27
hydroxyethyl starch. 56 73
Patients with cirrhosis and tense
ascites.
Choi et al. 2002 [21] Randomized trial; Jun 1998to Feb 2001; Korea.
40; 21 albumin; 19 no
albumin. 56 78
Patients with cirrhosis and
spontaneous bacterial peritonitis.
Fassio et al. 1992 [22] Randomized trial; Apr 1988to Mar 1990; Argentina.
40; albumin 21; dextran-70
20. 54 76
Patients with cirrhosis and tense
ascites.
Garcia-Compean
et al. 1993 [23]
Randomized trial; unclear
dates; Mexico.
35; 17 albumin; 18 no
albumin. 56 58
Patients with cirrhosis and tense
ascites.
Garc´ıa-Compean
et al. 2002 [24]
Randomized trial; unclear
dates; France.
69; albumin 48; dextran-40
48. 59 82
Patients with cirrhosis and tense
ascites.
Gines et al. 1988 [2] Randomized trial; Jul 1985 toDec 1986, Spain.
105; 52 albumin; 53 no
albumin. 57 66
Patients with cirrhosis and tense
ascites.
Gines et al. 1996 [25] Randomized trial; uncleardates, Spain.
289; albumin 97;
dextran-70 93; polygeline
99.
58 70 Patients with cirrhosis and tenseascites.
Guevara et al. 2012
[26]
Randomized trial; unclear
dates; Spain.
110; 56 albumin and
antibiotics; 54 antibiotics. 56 64
Patients with cirrhosis and
non-spontaneous bacterial peritonitis
infections.
Moreau et al. 2006
[27]
Randomized pilot study;
May 2000–Jun 2001; France.
68; 30 albumin; 38
polygeline. 55 82
Patients with cirrhosis and ascites who
needed to receive a plasma expander
because of paracentesis, renal
impairment or marked hyponatraemia.
Nazar et al. 2009 [28] Randomized trial; uncleardates; Spain.
110; 56 albumin and
antibiotics; 54 antibiotics. NA NA
Patients with cirrhosis and non-SBP
infections.
Planas et al. 1990 [29] Randomized trial; USA. 88; 43 albumin; 45dextran-70. 59 63
Patients with cirrhosis and tense
ascites treated with paracentesis.
Salemo 1991 [35] Randomized trial; May1986–July 1989; Italy.
54; 27 albumin; 27
hemaccel. 54 87
Patients with cirrhosis and refractory
ascites.
Sola-Vera et al. 2003
[30]
Randomized trial; Jan
1997–Dec 2000; Spain. 72; 37 albumin; 35 saline. 61 65
Patients with cirrhosis and tense
ascites.
Sort et al. 1999 [8] Randomized trial; Nov1995–Sept 1997; Spain.
126; 63 cefotaxime and
albumin; 63 cefotaxime. 61 64
Patients with cirrhosis and
spontaneous bacterial peritonitis.
Xue et al. 2002 [31] Randomized trial; uncleardates; China.
112; 56 albumin and
ceftriaxone; 56 ceftriaxone. NA NA
Patients with cirrhosis, ascites and
spontaneous bacterial peritonitis.
NA: not available.
25, 29, 34, 35] compared plasma expander to albumin. Four
other studies [26, 28, 31] of cirrhotic patients with infection
compared the use of antibiotics with and without albumin.
Study durations varied from 5 days to 27months.The process
of selection is shown in Figure 1 and the main characteristics
of the included studies are described in Table 1.The outcomes,
interventions, and quality assessments of the included studies
are shown in Table 2 and Supplementary Material 2.
For methodological quality assessment, the majority of
trials (10 trials) had adequate sequence generation for ran-
domization but only two trials had adequate allocation con-
cealment (Supplementary Material 2). Blinding of patients,
personnel, and outcome assessors was unclear in themajority
of studies and most studies did not have any evidence of
selective reporting and baseline difference.
3.1. Is Albumin Useful in Paracentesis? Three studies were
included in the analysis of whether albumin was useful in
paracentesis [2, 23, 30]. The use of albumin was associated
with significant reduction in paracentesis-induced circula-
tory dysfunction (OR 0.26 95% CI 0.08–0.93). No significant
difference was observed for the risk of any other outcomes
with and without albumin use. There was a nonsignificant
trend towards reduction in hyponatraemia, paracentesis-
induced circulatory dysfunction, readmission, and renal
impairment.
3.2. Is Albumin BetterThan Other Volume Expanders in Para-
centesis? Eight studies evaluated the use of volume expanders
compared to albumin [19, 20, 22, 24, 25, 29, 34, 35]. None
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Table 2: Treatment groups, followup, and results.
Study Albumin group Control group Duration of followup Results
Abdel-Khalek and
Arif 2010 [19]
Paracentesis and IV 20%
albumin 8 g/L of ascitic fluid
removed.
Paracentesis and
hydroxyethyl starch
6%.
Up to 11 months.
Bacterial infection 3/68 versus 3/67,
death 5/68 versus 6/67, encephalopathy
3/68 versus 2/67, GI bleeding 5/68
versus 5/67, readmissions 32/68 versus
37/67.
Altman et al. 1998
[20]
Paracentesis and IV 20%
albumin 100mL if <2 L of
ascites removed, 200mL if
2–5 L of ascitic fluid
removed.
Paracentesis and
hydroxyethyl starch
200mL/L of ascetics
fluid removed.
Up to 15 days after
paracentesis.
Encephalopathy 1/33 versus 0/27, GI
bleeding 0/33 versus 1/27,
hyponatraemia 0/33 versus 1/27, severe
infection 2/33 versus 3/27.
Choi et al. 2002 [21]
Paracentesis and albumin
6–8 g/L of ascitic fluid
removed.
General management. Followup at 7 days.
Death 3/21 versus 2/19, encephalopathy
2/21 versus 0/19, hyponatremia 4/21
versus 2/19, renal impairment 3/21
versus 1/19.
Fassio et al. 1992
[22]
Paracentesis with albumin
6 g/L of ascitic fluid removed.
Paracentesis with
dextran 70 6 g/L of
ascitic fluid removed.
In-hospital outcomes.
Death 6/21 versus 6/20,
encephalopathy 1/21 versus 2/20, GI
bleeding 3/21 versus 0/20,
hyponatremia 4/21 versus 3/20,
readmission 6/21 versus 5/20, renal
impairment 1/21 versus 1/20, sepsis
2/21 versus 1/20.
Garcia-Compean
et al. 1993 [23]
Paracentesis with albumin
5 g/L of ascitic fluid removed.
Paracentesis without
albumin. 5 days.
Encephalopathy 1/17 versus 0/18,
hyponatremia 1/17 versus 1/18, renal
impairment 1/17 versus 2/18.
Garc´ıa-Compean
et al. 2002 [24]
Paracentesis with albumin
infusion 8 g/L of ascitic fluid
removed.
Paracentesis with
8 g/L Dextran
solution (10mg
Dextran-40 and 5 g
sorbitol per 100mL)
14 months.
Death 11/48 versus 18/48,
hyponatremia 3/48 versus 5/48,
readmission 30/48 versus 34/48, renal
impairment 7/48 versus 2/48.
Gines et al. 1988 [2]
Paracentesis 4–6 L/day until
resolution and IV 20%
albumin infusion (40 g after
each tap).
Paracentesis without
albumin. 27 months.
Death 18/51 versus 14/50,
hyponatremia 1/51 versus 2/52,
readmission 29/51 versus 36/50, renal
impairment 0/51 versus 1/50.
Gines et al. 1996 [25]
Paracentesis with IV
albumin 8 g/L of ascitic fluid
removed.
Group II: Paracentesis
and IV dextran-70
(8 g/L of ascitic fluid)
and Group 3:
Paracentesis with IV
polygeline (8 g/L of
ascitic fluid).
NA
Bacterial infection 5/97 versus 3/99,
deaths 2/97 versus 6/99,
encephalopathy 3/97 versus 5/99, GI
bleeding 1/97 versus 1/99,
hyponatremia 14/97 versus 19/99,
PPCD 17/92 versus 37/98, renal
impairment 7/97 versus 10/99.
Guevara et al. 2012
[26]
Antibiotics plus 20%
albumin (1.5 g/kg then
1 g/kg).
Best infection care
with antibiotics but
not albumin.
3 months. Death 8/56 versus 10/54, renalimpairment 1/56 versus 4/54.
Moreau et al. 2006
[27]
Paracentesis and 20%
albumin replacement.
Paracentesis and 3.5%
polygeline. 6 months. Hyponatraemia 8/29 versus 15/38.
Nazar et al. 2009
[28]
Antibiotics plus albumin
(1.5 g/kg then 1 g/kg).
Best infection care
with antibiotics but
not albumin.
3 months.
Infection resolution 55/56 versus
50/54, renal impairment 3/56 versus
4/54.
Planas et al. 1990
[29]
Paracentesis and IV 20%
albumin 8 g/L of ascitic fluid
removed.
Paracentesis and
dextran-70 8 g/L
ascitic fluid removed.
27.5 weeks versus 23.7
weeks.
Death 13/43 versus 17/45,
encephalopathy 3/43 versus 3/45, GI
bleeding 1/43 versus 3/45,
hyponatraemia 3/43 versus 4/45,
readmissions 24/43 versus 29/43, renal
impairment 1/43 versus 1/45, severe
infection 1/43 versus 2/45.
Salemo 1991 [35]
Paracentesis and IV 20%
albumin 30mL/L of ascitic
fluid removed.
Paracentesis and IV
haemaccel 3.5%
150mL/L of ascitic
fluid removed.
NA.
Encephalopathy 2/27 versus 2/27,
hyponatraemia 4/27 versus 5/27,
readmissions 17/27 versus 12/27, renal
impairment 1/27 versus 1/27.
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Table 2: Continued.
Study Albumin group Control group Duration of followup Results
Sola-Vera et al. 2003
[30]
Paracentesis and IV 20%
albumin 8 g/L of ascitic fluid
removed.
Paracentesis and
170mL of 3.5%
saline/L of ascites
removed.
NA.
Death 1/37 versus 1/35, hyponatraemia
2/37 versus 5/35, PICD 4/37 versus
11/35, renal impairment 2/37 versus
3/35.
Sort et al. 1999 [8]
IV cefotaxime 2 g dosing
based on serum creatinine
and 20% albumin 1.5 g/kg
during first 6 hours, then
1 g/kg on day 3.
IV cefotaxime dosing
based on creatinine. NA.
Death in hospital 6/63 versus 18/63,
death at three months 14/63 versus
26/63, infection resolution 62/63
versus 59/63, renal impairment 6/63
versus 21/63.
Xue et al. 2002 [31]
IV ceftriaxone plus IV
albumin 0.5–1.0 g/kg within
6 hours of enrolment, then
same amount on 3rd day and
every 3 days thereafter.
IV ceftriaxone 3 g/day
adjusted based on
serum creatinine.
NA. Renal impairment 5/56 versus 19/56,deaths 5/56 versus 17/56.
NA: not available.
of these studies compared the use of albumin versus other
volume expanders outside of the paracentesis context. The
use of albumin resulted in no significant advantage in risk
of death, encephalopathy, hyponatraemia, gastrointestinal
bleeding, readmission, renal impairment, and sepsis/severe
infection.
3.3. Is Albumin Useful in Infections/Sepsis? Five studies were
included in the analysis of albumin use in sepsis. Two studies
[26, 28] included participants with non-SBP infection while
three studies included participants with SBP [8, 21, 31]. In the
context of any infection, the use of albumin was associated
with reduced risk of death OR 0.46 95% CI 0.25–0.86,
𝐼
2
= 24% and renal impairment OR 0.34 95% CI 0.15–
0.75, 𝐼2 = 34%. There was a nonsignificant trend towards
infection resolution and increased risk of hyponatraemia.
Subgroup analysis considering SBP showed that the albumin
use was associated with reduced risk of death. No significant
difference was observed for non-SBP infection (Table 3). The
pooled results of the risk evaluations are shown in Figure 2
and Table 2.
4. Discussion
Our results suggest that albumin has a value in the treatment
of cirrhotic patients in the contexts of large volume para-
centesis and infections. There is no significant advantage of
albumin compared to other plasma expanders for paracente-
sis. In paracentesis, albumin reduces the risk of paracentesis-
induced circulatory dysfunction. In cases of cirrhotic patients
with infections, death and renal impairment can be reduced
with the use of albumin. Therefore, cirrhotic patients at high
risk of circulatory dysfunction during paracentesis should
receive albumin or an alternative plasma expander, and
cirrhotic patients with sepsis or infection at high risk of renal
impairment or death should receive albumin.
Broadly, our findings support the AASLD and EASL
recommendations for the management of large volume
paracentesis [5, 6]. The use of other plasma expanders is
not supported as there is insufficient evidence according to
the guidelines. While albumin may cost more than plasma
expanders, the use of albumin is justified as there is evidence
that there are fewer 30-day liver related events among the
patients treated with albumin [27]. Both guidelines support
the use of albumin in spontaneous bacterial peritonitis [5, 6]
but there are currently no guidelines for non-SBP infections.
There are a number of potential explanations for our find-
ings. Human albumin is a major plasma protein and acts as
an intravascular volume expander. It is produced in the liver
and its concentration is reduced with hepatic dysfunction.
It is responsible for 80% of the colloid osmotic pressure of
plasma; therefore, the intravenous administration of albumin
is associated with a rapid increase in the circulating blood
volume. In the context of infection and sepsis, the acute
inflammatory response has a vasodilatory effect. This leads
to circulatory collapse which is compounded by a lack of
albumin to maintain oncotic pressure in the intravascular
compartment. In addition, it has other physiological func-
tions such as transport of water insoluble endogenous and
exogenous substances such as anti-inflammatory mediators,
hormones, and antibiotics in sepsis. It also acts as a circu-
latory antioxidant which may prevent cellular injury from
reactive oxygen species in sepsis and ischaemia.
Our review builds on the finding of the meta-analysis by
Bernardi et al. [36]. Similar to their findings, we found that
the use of albumin reduces the risk of paracentesis-induced
circulatory dysfunction. However, we did not find that there
was any significant differencewhen albuminwas compared to
other volume expanders. Their study was limited to patients
receiving paracentesis while our study also considers patients
with infection.
Our study has several advantages. All the studies included
were prospective randomized trials. We were able to consider
cirrhotic patients in several different settings including those
requiring paracentesis with tense ascites as well as those with
SBP and non-SBP infection. In addition, we were able to con-
sider a variety of outcomes including death, encephalopathy,
6 BioMed Research International
Albumin No albuminStudy or subgroup 
Events
Weight
TotalEventsTotal
1.1.1 Death
Choi 2002 3 21 2 19 6.1%
Guevara 2012 8 56 10 54 11.7%
Sort 1999 14 63 26 63 13.8%
Xue 2002 5 56 17 56 11.2%
Subtotal (95% CI) 196 192 42.9%
Total events 30 55
Choi 2002 4 21 2 19 6.5%
Subtotal (95% CI) 21 19 6.5%
Total events 4 2
Heterogeneity: Not applicable
1.1.3 Infection resolution
Nazar 2009 55 56 50 54 4.9%
Sort 1999 62 63 59 63 5.0%
Subtotal (95% CI) 119 117 9.9%
Total events 117 109
1.1.4 Renal impairment
Choi 2002 3 21 1 19 4.5%
Guevara 2012 1 56 4 54 4.9%
Nazar 2009 3 56 4 54 8.0%
Sort 1999 6 63 21 63 12.0%
Xue 2002 5 56 19 56 11.3%
Subtotal (95% CI) 252 246 40.7%
Total events 18 49
Test for overall effect: Z = 2.46 (P = 0.01)
Test for overall effect: Z = 0.74 (P = 0.46)
Test for overall effect: Z = 1.82 (P = 0.07)
Test for overall effect: Z = 2.65 (P = 0.008)
Heterogeneity: 𝜏2 = 0.00; 𝜒2 = 0.00, df = 1 (P = 0.98); I2 = 0%
Heterogeneity: 𝜏2 = 0.09; 𝜒2 = 3.93, df = 3 (P = 0.27); I2 = 24%
Heterogeneity: 𝜏2 = 0.28; 𝜒2 = 6.09, df = 4 (P = 0.19); I2 = 34%
Odds ratio Odds ratio
M-H, random, 95% CI M-H, random, 95% CI
1.42 [0.21, 9.55]
0.73 [0.27, 2.02]
0.41 [0.19, 0.88] 
 0.22 [0.08, 0.66] 
0.46 [0.25, 0.86]
2.00 [0.32, 12.41]
2.00 [0.32, 12.41]
4.40 [0.48, 40.70]
4.20 [0.46, 38.71]
4.30 [0.89, 20.70]
3.00 [0.28, 31.63]
0.23 [0.02, 2.10]
0.71 [0.15, 3.32]
0.21 [0.08, 0.57]
0.19 [0.07, 0.56]
0.34 [0.15, 0.75]
1.1.2 Hyponatraemia
0.01 0.1 
Favours albumin
1 10 100 
Favours no albumin 
Figure 2: Albumin versus no albumin among cirrhotic patients with infections.
hyponatraemia, paracentesis-induced circulatory dysfunc-
tion, readmission renal impairment, gastrointestinal bleed,
infection resolution, and sepsis/severe infection.
There are several limitations in this review. The quality
of the studies is generally poor as blinding was not used.
Furthermore, the sample size of the studies is small and only
a few studies were included in each pooled analysis. The
duration of followup was also variable among the studies.
We would recommend three studies of albumin and
plasma expanders which are in the context of paracentesis,
non-SBP, and SBP infections. In addition to clinical outcomes
such as need for death, encephalopathy, hyponatraemia, GI
bleeding, readmission, renal impairment, sepsis, and need for
liver transplant, this study should further consider the cost
implications. The most important of the possible studies is
that of albumin versus plasma expanders in infections (non-
SBP and SBP) as these questions have not been answered.
In addition, a study of different doses of albumin could help
determine the dosing regimen that would lead to the best
clinical outcomes. We believe that the ideal trial would be
an adequately powered multicentre double-blinded trial that
has followup of at least 1 month and corrects for liver disease
severity.
5. Conclusions
In conclusion, the findings of this meta-analysis support the
use of albumin for preventing paracentesis-induced circula-
tory collapse and reducing the risk of death and renal failure
in cirrhotic patients with infections limited to SBP. More
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Table 3: Summary of results.
Outcome or subgroup Studies Participants Odds ratio (95% confidence interval)
Is albumin useful in paracentesis?
1.1.1 Death 2 173 1.36 (0.61, 3.04)
1.1.2 Encephalopathy 1 35 3.36 (0.13, 88.39)
1.1.3 Hyponatraemia 3 210 0.47 (0.13, 1.66)
1.1.4 Paracentesis-induced circulatory dysfunction 1 72 0.26 (0.08, 0.93)
1.1.5 Readmission 1 101 0.51 (0.22, 1.18)
1.1.6 Renal impairment 3 208 0.51 (0.13, 1.98)
Is albumin better than other volume expander in paracentesis?
1.2.1 Death 5 556 0.63 (0.38, 1.03)
1.2.2 Encephalopathy 6 574 0.87 (0.42, 1.80)
1.2.3 Hyponatraemia 7 602 0.70 (0.44, 1.12)
1.2.4 Gastrointestinal bleeding 5 520 0.90 (0.35, 2.31)
1.2.5 Readmission 5 412 0.83 (0.56, 1.24)
1.2.6 Renal impairment 5 475 1.09 (0.51, 2.34)
1.2.7 Sepsis/severe infection 3 189 0.74 (0.21, 2.62)
Is albumin useful in infections overall?
1.3.1 Death 4 388 0.46 (0.25, 0.86)
1.3.2 Hyponatraemia 1 40 2.00 (0.32, 12.41)
1.3.3 Infection resolution 2 236 4.30 (0.89, 20.70)
1.3.4 Renal impairment 5 498 0.34 (0.15, 0.75)
Is albumin useful in spontaneous bacterial peritonitis?
1.4.1 Death 3 278 0.39 (0.18, 0.84)
1.4.2 Infection resolution 1 126 4.20 (0.46, 38.71)
1.4.3 Renal impairment 3 278 0.32 (0.10, 1.04)
Is albumin useful in non-spontaneous bacterial peritonitis infections?
1.5.1 Death 1 110 0.73 (0.27, 2.02)
1.5.2 Infection resolution 1 110 4.40 (0.48, 40.70)
1.5.3 Renal impairment 1 110 0.23 (0.02, 2.10)
studies are needed to evaluate if albumin reduces adverse
outcomes among cirrhotic patients without paracentesis or
infections.There is no evidence to support the use of albumin
over other plasma expanders for paracentesis.
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